Clinical study on the therapeutic efficacy of Edaravone in acute cerebral infarction

Abstract

Objective To investigate the effect and safety of edavarone in the treatment of acute cerebral infarction. Methods Totally, 120 patients, admitted to Department of Neurology of Yanbian University Hospital from January 2018 to January 2019, were randomly divided into control group (60 cases) and observation group (60 cases). Both groups were given conventional treatment, but the patients in observation group were given edaravone additonally. On 14 and 21 d after treatment, the clinical effect was evaluated using the chart of ADL and NIHSS. Results The therapeutic effective rates were 88.33% and 73.33% for observation group and control group, respectively. Meanwhile, significant improvement could be seen by the score of ADL and NIHSS on day 7 and day 14 after treatment in observation group, and there was significant difference between these two groups. More, no severe drug associated side-effect were observed in each group. Conclusion Edavarone can improve neurological deficits as well ADL score in acute cerebral infarction patients, resulting in good therapeutic efficacy, and it is worth of application as a safe drug. Key words: Edaravone; Acute cerebral infarction; Neurological function deficits